泰格醫藥(03347.HK)擬參與認購嘉和生物首次公開發行股份
格隆匯 9 月 23日丨泰格醫藥(03347.HK)公告,第四屆監事會第五次會議決議。審議並通過《關於全資子公司作為基石投資者參與嘉和生物藥業(開曼)控股有限公司香港首次公開發行的議案》。
本次公司全資子公司HONGKONGTIGERMEDHEALTHCARETECHNOLOGYCO.,LIMITED使用自籌資金約2,200萬美元,以基石投資者的身份參與認購嘉和生物在香港聯合交易所的首次公開發行股份,有利於公司利用在醫藥臨牀研究領域的專業優勢,拓展投資渠道,獲取投資收益,促進公司國際化戰略目標的實現,符合全體股東的利益。
因此,監事會同意該議案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.